Arterra Bioscience Profit Margin

Arterra Bioscience posts a profit margin of 37.17% as of June 2026. That compares with 34.89% in the prior-year period — up 6.5% year over year. That is above the Healthcare sector average of 9.48%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Arterra Bioscience's profit margin was 34.89%. The latest reading is 37.17% — a 6.5% year-over-year increase (period ending June 2026). Use the history and growth charts on this page for a longer lookback.

For Healthcare stocks, a profit margin near 9.48% is typical. Arterra Bioscience's 37.17% is higher that level. That is roughly 292.0% above the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Arterra Bioscience's profit margin moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is 37.17% as of June 2026; use YoY and peer views to separate noise from signal.

Context for ARBS.MI's profit margin usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 9.48%), and (3) consistency with growth and profitability. This page covers the first two; Arterra Bioscience's other metric pages and overview cover the third.